Showing results (461-470 of 526) with videos related to
Sort By:
Pageof 53
Molecular Cancer Therapeutics|December 29, 2011
CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancersMangeng Cheng, Matthew R Quail, Diane E Gingrich, et al.ESMO Open|September 6, 2024
High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMTS Secondino, M Badoglio, G Rosti, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 2, 2011
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2Lily D Lu, Kristine L Stump, Nate H Wallace, et al.Placenta|October 19, 2025
Chronic mild maternal stress modulates the immune response at the maternal-fetal interface and affects the growth and mortality of the offspringF L De la Cruz Borthiry, J S Beltrame, V A Cañumil, et al.Bone Marrow Transplantation|September 9, 2025
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendationsR Greco, A Ruggeri, D P McLornan, et al.Leukemia|May 5, 2012
Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysisA Ruggeri, G Michel, J-H Dalle, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activityGregory R Ott, Rabindranath Tripathy, Mangeng Cheng, et al.Journal of Endocrinological Investigation|November 15, 2011
Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management studyA Faggiano, P Ferolla, F Grimaldi, et al.Journal of Medicinal Chemistry|December 4, 2003
A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055Diane E Gingrich, Dandu R Reddy, Mohamed A Iqbal, et al.Journal of Medicinal Chemistry|December 14, 2011
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agentRobert L Hudkins, Nadine C Becknell, Allison L Zulli, et al.Pageof 53